[A18-56] Tofacitinib (rheumatoid arthritis) - Addendum to Commission A18-28
Last updated 07.11.2018
Project no.:
A18-56
Commission:
Commission awarded on 11.09.2018 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Muscles, bones and joints
bDMARD-naive adults with moderate to severe active rheumatoid arthritis for whom a first treatment with a bDMARD is indicated
Based on the data subsequently submitted on serious infections, the added benefit is now not proven
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Accompanying information| Project no. | Title | Status |
|---|---|---|
| A18-28 | Tofacitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V (expiry of the decision) | Commission completed |
Federal Joint Committee (G-BA)
2018-11-07 A G-BA decision was published.